Abstract:Objective Glucocorticoid (GC) excess decreases bone mineralization and microarchitecture and lead to reduced bone strength. Both anabolic agent parathroid hormone (PTH) and anti-resorptive agent alendronate (ALN) are used to prevent and treat GC-induced bone loss, yet these bone active agents alter bone turnover by very different mechanisms. Our study was to determine how PTH and ALN alter bone quality following GC excess.Methods Nine-month-old SD male rats were treated with methylprednisolone (5 mg/kg·d) or placebo (CON). Other two groups of GC-treated rats had either PTH(80 μg/kg·d) or ALN(4 mg/kg·d) intervention. All the animals were killed after 3 months, and femur and tibia isolated for indicated detection. Bone quality and quantity measurements were measured by dual x-ray absorptiometry (DEXA) for the degree of bone mineralization, histomorphometry for bone microarchitecture, biochemistry for bone turnover. Osteoblasts isolated from newborn rats were cultured in vitro. Cells were treated with 1) CON: placebo; 2)GC: Dexamethasone 10-5mol/L; 3) ALN: Alendronate 10-7mol/L; 4)PTH: human recombinant parathyroid hormone 10-7mol/L; 5)GC+ALN: Dexamethasone 10-5mol/L+ALN 10-7mol/L; 6)GC+PTH: Dexamethasone 10-5mol/L+ PTH 10-7mol/L. Osteoblast proliferation and osteogenic activity were identified by MTT, alkaline phosphatase detection, calcium nodules were observed by Alizarin red staining, and real-time PCR were performed to monitor the expression of several key genes regulating bone formation and mineralization as FGF23 and SOST.Results Spine and Femur BMD was reduced after GC treatment, and it was restored to CON level with GC+ALN and GC+PTH at site of femur and spine separately (P<0.05). Compared to the CON, GC treatment decreased trabecular bone volume, bone formation rate, mineral apposition rate and serum BGP, but increased osteoclast surface and serum TRAP5b (P<0.05). GC+PTH increased and GC+ALN restored trabecular bone volume to the CON levels (P<0.05 compared to GC). GC+PTH increased bone formation rate and serum BGP compared to GC (P<0.05), while GC+ALN increased mineral apposition rate (P<0.01) and reduced osteoclast surface and serum TRAP5b compared to GC (P<0.05). As to osteoblasts experiments, GC treatment decrease MTT and AKP activity, reduced calcium nodules significantly (P<0.05 compared to CON), however, GC+PTH and GC+ALN promoted osteoblast MTT and AKP to the CON levels, but PTH significantly inhibited the calcium nodules, whereas ALN increased it. Realtime-PCR revealed that SOST and FGF23 were up-regulated by GC treatment (P<0.05 compared to CON), but SOST gene was down-regulated after GC+PTH treatment (P<0.01 compared to GC), while SOST and FGF23 genes were both down-regulated by GC+ALN treatment (P<0.05 compared to GC). Conclusion GC excess increased expression of gene that inhibit osteoblast activity and gene that inhibit mineralization and which were associated with reduced bone formation and bone volume. The addition of both PTH and ALN improved bone mass and bone strength during concurrent GC treatment, with PTH lowering expression of SOST and increasing bone formation; while ALN lowered the expression of SOST and FGF23 and reversed the deterioration of bone mineralization induced by GC excess.

FRI0324 Dkk-1 and Rankl/opg Predict Changes in Bone Mineral Density and Bone Microstructure in Sle on Long-Term Glucocorticoid: a Prospective Study

FRI0325 Sle Disease Per Se, Rather Than Glucocorticoid Treatment, Contributes More to Deterioration in Bone Density, Microstructure and Strength

MDR1(ABCB1) Gene Polymorphisms Associated with Steroid-Induced Osteonecrosis of Femoral Head in Systemic Lupus Erythematosus.

The significance of bone markers in the prediction of glucocorticoid-induced osteoporosis in patients with autoimmune diseases

Serum RANKL, OPG and Vitamin D in Children with Systemic Lupus Erythematosus

Study of Bone Mineral Density and Serum Bone Turnover Markers in Newly Diagnosed Systemic Lupus Erythematosus Patients

The clinical assessment of changes in bone density in Rheumatoid Arthritis patients': Role of DEXA scan and bone turnover biomarkers

Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis

OP0187 Transgenic Disruption of Glucocorticoid-Signaling in Mature Osteoblasts and Osteocytes Attenuates Structural Bone Damage in a Long-Term Murine K/bxn Serum-Induced Arthritis Model

THU420 Analysis Of Factors Affecting Bone Mineral Density In Children And Adolescents With Systemic Lupus Erythematosus

P617 Persistent active inflammation may predict non-improvement in bone mass density in patients with Crohn's disease

Impact of Treat-to-Target Therapy on Bone Mineral Density Loss in Patients with Rheumatoid Arthritis: A Prospective Cohort Study

Potential therapeutic targets of alendronate and PTH for glucocorticoid-induced bone loss

Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison's disease

Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis

Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT

Dickkopf-1 as Potential Biomarker to Evaluate Bone Erosion in Systemic Lupus Erythematosus

Factors affecting bone mineral density in children and adolescents with secondary osteoporosis

Determinants of bone mineral density in systemic lupus erythematosus

Risk factors for bone mineral density changes in 38 female connective tissue diseases patients who were taking glucocorticoid

Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides-Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort